WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 407922
Description: UM-164 is a Potent c-Src/p38 Kinase Inhibitor with In Vivo Activity against Triple-Negative Breast Cancer.
MedKoo Cat#: 407922
Chemical Formula: C30H31F3N8O3S
Exact Mass: 640.2192
Molecular Weight: 640.6862
Elemental Analysis: C, 56.24; H, 4.88; F, 8.90; N, 17.49; O, 7.49; S, 5.00
Synonym: UM-164; UM 164; UM164.
IUPAC/Chemical Name: 2-[[6-[4-(2-Hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-N-[2-methyl-5-[[3-(trifluoromethyl)benzoyl]amino]phenyl]-5-thiazolecarboxamide
InChi Key: ANEBQUSWQAQFQB-UHFFFAOYSA-N
InChi Code: InChI=1S/C30H31F3N8O3S/c1-18-6-7-22(37-27(43)20-4-3-5-21(14-20)30(31,32)33)15-23(18)38-28(44)24-17-34-29(45-24)39-25-16-26(36-19(2)35-25)41-10-8-40(9-11-41)12-13-42/h3-7,14-17,42H,8-13H2,1-2H3,(H,37,43)(H,38,44)(H,34,35,36,39)
SMILES Code: O=C(C1=CN=C(NC2=NC(C)=NC(N3CCN(CCO)CC3)=C2)S1)NC4=CC(NC(C5=CC=CC(C(F)(F)F)=C5)=O)=CC=C4C
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >3 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.03.00
The following data is based on the product molecular weight 640.6862 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||1.15 mL||5.76 mL||11.51 mL|
|5 mM||0.23 mL||1.15 mL||2.3 mL|
|10 mM||0.12 mL||0.58 mL||1.15 mL|
|50 mM||0.02 mL||0.12 mL||0.23 mL|
1: Ndagi U, Mhlongo NN, Soliman ME. Emergence of a Promising Lead Compound in the
Treatment of Triple Negative Breast Cancer: An Insight into Conformational
Features and Ligand Binding Landscape of c-Src Protein with UM-164. Appl Biochem
Biotechnol. 2017 Dec 27. doi: 10.1007/s12010-017-2677-z. [Epub ahead of print]
PubMed PMID: 29282631.
2: Ndagi U, Mhlongo NN, Soliman ME. The impact of Thr91 mutation on c-Src
resistance to UM-164: molecular dynamics study revealed a new opportunity for
drug design. Mol Biosyst. 2017 May 30;13(6):1157-1171. doi: 10.1039/c6mb00848h.
PubMed PMID: 28463369.
3: Gilani RA, Phadke S, Bao LW, Lachacz EJ, Dziubinski ML, Brandvold KR, Steffey
ME, Kwarcinski FE, Graveel CR, Kidwell KM, Merajver SD, Soellner MB. UM-164: A
Potent c-Src/p38 Kinase Inhibitor with In Vivo Activity against Triple-Negative
Breast Cancer. Clin Cancer Res. 2016 Oct 15;22(20):5087-5096. Epub 2016 May 6.
PubMed PMID: 27154914.